Answers are grounded in this paper and cite their sources.
The cost to develop a cancer drug is $648.0 million, a figure significantly lower than prior estimates. The revenue since approval is substantial (median, $1658.4 million; range, $204.1 million to $22 275.0 million). This analysis provides a transparent estimate of R&D spending on cancer drugs and has implications for the current debate on drug pricing.
No takes yet. Share an insight, caveat, or question.
Prasad et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: